Recruiting PHASE1 Muscle Invasive Bladder Cancer

New treatment option for Muscle Invasive Bladder Cancer

Official title Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

ClinicalTrials.gov ID: NCT06916494

What this study is testing

What is Rutin?

Rutin is an investigational medicine, being studied as a potential treatment for muscle invasive bladder cancer.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This trial aims to evaluate the efficacy, safety, and biological mechanisms of rutin combined with tislelizumab and GC(Gemcitabine and Cisplatin) in platinum-refractory muscle-invasive bladder cancer patients. Key research questions include: 1.
  • Phase 1: an early, usually small safety study

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Patients with cT2-cT4N0M0 muscle-invasive bladder cancer (MIBC)
  • No response after 2 cycles of GC neoadjuvant chemotherapy
  • No prior use of systemic immunotherapy or target therapy
  • Tumor is measurable according to New response evaluation criteria in solid tumours: Revised RECIST guideline
  • ECOG (ZPS, 5-point scale) 0-1

You likely can't join if

  • Age less than 18 years
  • Patients with severe cardiac, cerebral, hepatic, or renal disease
  • Severely malnourished patients
  • Patients with mental illness and those without insight and unable to express exactly
  • Combined with malignant tumors of other organs
  • Systemic infectious diseases

The study team makes the final eligibility decision.

Where it's taking place

  • Chongqing, Chongqing Municipality, China

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Chongqing, Chongqing Municipality, China. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.